Microcap Ledger Cytosorbents Corp $CTSO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Princeton, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 62,842,748 [10-Q 2026-08-06]
What the company doesAI summary of filing
CytoSorbents develops and commercializes blood purification technologies based on porous polymer beads that remove toxic substances from blood. The company generates revenue from three marketed products: CytoSorb, approved in the European Union and distributed in over 70 countries with more than 300,000 devices used cumulatively; ECOS-300CY for organ transplant preservation, approved in the E.U.; and VetResQ for veterinary critical care, commercialized primarily in the U.S. The company is also developing DrugSorb-ATR, an investigational device to reduce bleeding complications from blood thinners during cardiac surgery, which has received FDA Breakthrough Device Designation but is not yet approved in the U.S. or Canada. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $18.50M | −$9.55M | −$1.75M | $4.41M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $37.06M | −$8.20M | −$12.38M | $6.25M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $35.59M | −$20.72M | −$14.43M | $3.28M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$872.5K
- Cash runway Estimate
- ~15.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 54,679,569 | [10-Q 2024-11-07] |
| 2025-03-31 | 62,500,000 | [10-K 2025-03-31] |
| 2025-05-13 | 62,610,376 | [10-Q 2025-05-14] |
| 2025-08-01 | 62,761,805 | [10-Q 2025-08-07] |
| 2025-11-10 | 62,804,305 | [10-Q 2025-11-13] |
| 2026-03-20 | 62,700,000 | [10-K/A 2026-04-15] |
| 2026-05-07 | 62,794,748 | [10-Q 2026-05-13] |
| 2026-07-31 | 62,842,748 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2024-07-26; declared effective 2024-09-30 [S-3 2024-07-26]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-06] |
| 2026-04-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-02] |
| 2025-10-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Chan Phillip P. | buy | 3,774 | $6.00 | [4 2026-09-16] |
| 2026-09-15 | Sobel Alan D. | buy | 1,900 | $6.12 | [4 2026-09-16] |
| 2026-09-15 | Sobel Alan D. | buy | 500 | $6.05 | [4 2026-09-16] |
| 2026-09-15 | Sobel Alan D. | buy | 100 | $6.01 | [4 2026-09-16] |
| 2026-09-14 | Capponi Vincent | buy | 1,800 | $6.07 | [4 2026-09-16] |
| 2026-09-14 | Capponi Vincent | buy | 273 | $5.90 | [4 2026-09-16] |
| 2026-09-04 | Chan Phillip P. | buy | 200,000 | $0.35 | [4 2026-09-09] |
| 2026-06-15 | Mariani Peter J | buy | 100,000 | $0.44 | [4 2026-06-16] |
| 2026-06-15 | Chan Phillip P. | buy | 10,333 | $0.43 | [4 2026-06-15] |
| 2026-06-12 | Chan Phillip P. | buy | 251,136 | $0.40 | [4 2026-06-15] |
| 2025-11-18 | Chan Phillip P. | grant | 100,000 | $0.64 | [4 2025-11-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-23 | 8-K | Regulation FD disclosure; Other events |
| 2026-09-08 | 8-K | Charter, bylaws or fiscal year change |
| 2026-08-14 | 8-K | Shareholder vote results |
| 2026-08-07 | 8-K | Regulation FD disclosure |
| 2026-08-06 | 8-K | Results of operations |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-06 | 8-K | Listing notice or transfer |
| 2026-06-25 | DEF 14A | Proxy statement |
| 2026-06-25 | 8-K | Regulation FD disclosure |
| 2026-06-11 | PRE 14A | Proxy statement |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
Alerts for $CTSO
Email me when Cytosorbents Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.